Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600551 | 1.00 | KDM4E (0.43) | KDM4ECYP2C9CYP2C19POLBNPSR1 | |
| SCHEMBL25600554 | 0.87 | CNR1 (0.34) | KDM4ECYP2C9CYP2C19L3MBTL1ALDH1A1 | |
| SCHEMBL25600556 | 0.87 | CNR1 (0.34) | KDM4ECYP2C9CYP2C19L3MBTL1ALDH1A1 | |
| SCHEMBL25605839 | 0.85 | EPHX1 (0.35) | L3MBTL1ALDH1A1KMT2AMEN1NPC1 | |
| SCHEMBL25631004 | 0.82 | KDM4E (0.52) | KDM4ECYP2C9CYP2C19POLBNPSR1 | |
| SCHEMBL25631005 | 0.82 | KDM4E (0.52) | KDM4ECYP2C9CYP2C19POLBNPSR1 | |
| SCHEMBL16643863 | 0.75 | PTPN1 (0.54) | KDM4ECYP2C9CYP2C19POLBNPSR1 | |
| SCHEMBL25604717 | 0.74 | KDM4E (0.42) | KDM4ECYP2C19POLBALDH1A1KMT2A | |
| SCHEMBL25600401 | 0.74 | HRH3 (0.48) | CYP2C19L3MBTL1 | |
| SCHEMBL25600400 | 0.74 | HRH3 (0.48) | CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | KDM4E 223/4885CYP2C9 2899/4885CYP2C19 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.